Progress Valley 2

Progress Valley 2 is a SAMHSA-registered addiction-treatment facility located at Minneapolis, MN. The facility offers a continuum of care across multiple levels — Inpatient, Outpatient, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Progress Valley 2

The facility offers a continuum of care across multiple levels — Inpatient, Outpatient, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of Progress Valley 2's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

Payment and insurance posture: Progress Valley 2 accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Clients with co-occurring mental and substance use disorders. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission documentation for Progress Valley 2 should include ASAM-framework level-of-care justification, plan-specific Verification of Benefits with network-contract confirmation, written MAT policy for opioid use disorder patients where applicable, and licensure/accreditation verification. If the clinical situation involves opioid use disorder, confirm explicitly whether Progress Valley 2 offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.